---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000449"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:58:35.794641+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences licenses tildacerfont to Kaken for Japan; $15M upfront, up to $65M milestones

## Summary
- Exclusive Japan rights for tildacerfont in CAH; $15M upfront, up to ~$65M in development/regulatory/commercial milestones.
- Preliminary cash, cash equivalents and investments as of Dec 31, 2022: approximately $79M (unaudited).
- Pediatric CAH trial amended: study length increased to 12 weeks plus 2-year open-label extension; age lowered to 2 years.
- Additional data to be collected: PK at 50mg and 200mg doses, A4 reduction, GC reduction, and 12-week safety data.

## SEC filing metadata
- accession: 0000950170-23-000449
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017023000449/0000950170-23-000449-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017023000449/sprb-20230105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000449
- JSON: https://secwatch.observer/filing/0000950170-23-000449.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000449.txt

## Key facts
- Material Agreements
  SPRUCE BIOSCIENCES, INC. entered into Collaboration and License Agreement with Kaken Pharmaceutical Co., LTD. valued at $15.0 million (effective 2023-01-05).
  - Action: entry
  - Agreement: license
  - Counterparty: Kaken Pharmaceutical Co., LTD.
  - Value: $15.0 million
  - Effective: 2023-01-05
  source text: On January 5, 2023, Spruce Biosciences, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Agreement”) with Kaken Pharmaceutical Co., LTD. (“Kaken”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1683553/000095017023000449/0000950170-23-000449-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.